Divalproex utility in bipolar disorder with co-occurring cocaine dependence: A pilot study

Ihsan M Salloum, Antoine Douaihy, Jack R. Cornelius, Levent Kirisci, Thomas M. Kelly, Jeanine Hayes

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: The aim of this open-label pilot study was to evaluate the utility of divalproex in decreasing cocaine use and stabilizing mood symptoms among patients with bipolar disorder with comorbid cocaine dependence. Method: Fifteen patients enrolled in the study and seven met final inclusion criteria of DSM-IV/SCID diagnoses of bipolar I disorder and comorbid cocaine dependence with active cocaine use. Patients were started on open-label divalproex. After stabilization on divalproex sodium, weekly assessments were undertaken for 8 weeks. Subjects also attended dual recovery counseling. Results: The results revealed significant improvement on % cocaine abstinent days, dollars spent on cocaine, ASI's drug use severity index, % alcohol abstinent days, drinks per drinking day, marijuana use and cigarettes smoking. They also had significant improvement on manic, depressive, and sleep symptoms and on functioning. There were no reported adverse events or increases in liver function tests. Conclusion: The results of this open-label study point to the potential utility of divalproex in patients with bipolar disorder and primary cocaine dependence. Double-blind, placebo-controlled studies to fully evaluate the efficacy of divalproex in this high risk clinical population are warranted.

Original languageEnglish
Pages (from-to)410-415
Number of pages6
JournalAddictive Behaviors
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Cocaine-Related Disorders
Valproic Acid
Bipolar Disorder
Cocaine
Labels
Marijuana Smoking
Liver Function Tests
Diagnostic and Statistical Manual of Mental Disorders
Drinking
Counseling
Sleep
Smoking
Cannabis
Placebos
Alcohols
Depression
Tobacco Products
Liver
Stabilization
Pharmaceutical Preparations

Keywords

  • Bipolar disorder
  • Cocaine dependence
  • Comorbidity
  • Divalproex
  • Dual diagnosis
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Divalproex utility in bipolar disorder with co-occurring cocaine dependence : A pilot study. / Salloum, Ihsan M; Douaihy, Antoine; Cornelius, Jack R.; Kirisci, Levent; Kelly, Thomas M.; Hayes, Jeanine.

In: Addictive Behaviors, Vol. 32, No. 2, 01.02.2007, p. 410-415.

Research output: Contribution to journalArticle

Salloum, Ihsan M ; Douaihy, Antoine ; Cornelius, Jack R. ; Kirisci, Levent ; Kelly, Thomas M. ; Hayes, Jeanine. / Divalproex utility in bipolar disorder with co-occurring cocaine dependence : A pilot study. In: Addictive Behaviors. 2007 ; Vol. 32, No. 2. pp. 410-415.
@article{d907c20c1c5c4659b04e580ba950e5ba,
title = "Divalproex utility in bipolar disorder with co-occurring cocaine dependence: A pilot study",
abstract = "Objective: The aim of this open-label pilot study was to evaluate the utility of divalproex in decreasing cocaine use and stabilizing mood symptoms among patients with bipolar disorder with comorbid cocaine dependence. Method: Fifteen patients enrolled in the study and seven met final inclusion criteria of DSM-IV/SCID diagnoses of bipolar I disorder and comorbid cocaine dependence with active cocaine use. Patients were started on open-label divalproex. After stabilization on divalproex sodium, weekly assessments were undertaken for 8 weeks. Subjects also attended dual recovery counseling. Results: The results revealed significant improvement on {\%} cocaine abstinent days, dollars spent on cocaine, ASI's drug use severity index, {\%} alcohol abstinent days, drinks per drinking day, marijuana use and cigarettes smoking. They also had significant improvement on manic, depressive, and sleep symptoms and on functioning. There were no reported adverse events or increases in liver function tests. Conclusion: The results of this open-label study point to the potential utility of divalproex in patients with bipolar disorder and primary cocaine dependence. Double-blind, placebo-controlled studies to fully evaluate the efficacy of divalproex in this high risk clinical population are warranted.",
keywords = "Bipolar disorder, Cocaine dependence, Comorbidity, Divalproex, Dual diagnosis, Treatment",
author = "Salloum, {Ihsan M} and Antoine Douaihy and Cornelius, {Jack R.} and Levent Kirisci and Kelly, {Thomas M.} and Jeanine Hayes",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.addbeh.2006.05.007",
language = "English",
volume = "32",
pages = "410--415",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Divalproex utility in bipolar disorder with co-occurring cocaine dependence

T2 - A pilot study

AU - Salloum, Ihsan M

AU - Douaihy, Antoine

AU - Cornelius, Jack R.

AU - Kirisci, Levent

AU - Kelly, Thomas M.

AU - Hayes, Jeanine

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Objective: The aim of this open-label pilot study was to evaluate the utility of divalproex in decreasing cocaine use and stabilizing mood symptoms among patients with bipolar disorder with comorbid cocaine dependence. Method: Fifteen patients enrolled in the study and seven met final inclusion criteria of DSM-IV/SCID diagnoses of bipolar I disorder and comorbid cocaine dependence with active cocaine use. Patients were started on open-label divalproex. After stabilization on divalproex sodium, weekly assessments were undertaken for 8 weeks. Subjects also attended dual recovery counseling. Results: The results revealed significant improvement on % cocaine abstinent days, dollars spent on cocaine, ASI's drug use severity index, % alcohol abstinent days, drinks per drinking day, marijuana use and cigarettes smoking. They also had significant improvement on manic, depressive, and sleep symptoms and on functioning. There were no reported adverse events or increases in liver function tests. Conclusion: The results of this open-label study point to the potential utility of divalproex in patients with bipolar disorder and primary cocaine dependence. Double-blind, placebo-controlled studies to fully evaluate the efficacy of divalproex in this high risk clinical population are warranted.

AB - Objective: The aim of this open-label pilot study was to evaluate the utility of divalproex in decreasing cocaine use and stabilizing mood symptoms among patients with bipolar disorder with comorbid cocaine dependence. Method: Fifteen patients enrolled in the study and seven met final inclusion criteria of DSM-IV/SCID diagnoses of bipolar I disorder and comorbid cocaine dependence with active cocaine use. Patients were started on open-label divalproex. After stabilization on divalproex sodium, weekly assessments were undertaken for 8 weeks. Subjects also attended dual recovery counseling. Results: The results revealed significant improvement on % cocaine abstinent days, dollars spent on cocaine, ASI's drug use severity index, % alcohol abstinent days, drinks per drinking day, marijuana use and cigarettes smoking. They also had significant improvement on manic, depressive, and sleep symptoms and on functioning. There were no reported adverse events or increases in liver function tests. Conclusion: The results of this open-label study point to the potential utility of divalproex in patients with bipolar disorder and primary cocaine dependence. Double-blind, placebo-controlled studies to fully evaluate the efficacy of divalproex in this high risk clinical population are warranted.

KW - Bipolar disorder

KW - Cocaine dependence

KW - Comorbidity

KW - Divalproex

KW - Dual diagnosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33845508047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845508047&partnerID=8YFLogxK

U2 - 10.1016/j.addbeh.2006.05.007

DO - 10.1016/j.addbeh.2006.05.007

M3 - Article

C2 - 16814474

AN - SCOPUS:33845508047

VL - 32

SP - 410

EP - 415

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

IS - 2

ER -